Literature DB >> 17624830

HIV infection and multidrug-resistant tuberculosis: the perfect storm.

Charles D Wells1, J Peter Cegielski, Lisa J Nelson, Kayla F Laserson, Timothy H Holtz, Alyssa Finlay, Kenneth G Castro, Karin Weyer.   

Abstract

BACKGROUND: Multidrug-resistant (MDR) tuberculosis (TB) has emerged as a global epidemic, with ~425,000 new cases estimated to occur annually. The global human immunodeficiency virus (HIV) infection epidemic has caused explosive increases in TB incidence and may be contributing to increases in MDR-TB prevalence.
METHODS: We reviewed published studies and available surveillance data evaluating links between HIV infection and MDR-TB to quantify convergence of these 2 epidemics, evaluate the consequences, and determine essential steps to address these epidemics.
RESULTS: Institutional outbreaks of MDR-TB have primarily affected HIV-infected persons. Delayed diagnosis, inadequate initial treatment, and prolonged infectiousness led to extraordinary attack rates and case-fatality rates among HIV-infected persons. Whether this sequence occurs in communities is less clear. MDR-TB appears not to cause infection or disease more readily than drug-susceptible TB in HIV-infected persons. HIV infection may lead to malabsorption of anti-TB drugs and acquired rifamycin resistance. HIV-infected patients with MDR-TB have unacceptably high mortality; both antiretroviral and antimycobacterial treatment are necessary. Simultaneous treatment requires 6-10 different drugs. In HIV-prevalent countries, TB programs struggle with increased caseloads, which increase the risk of acquired MDR-TB. Surveillance data suggest that HIV infection and MDR-TB may converge in several countries.
CONCLUSIONS: Institutional outbreaks, overwhelmed public health programs, and complex clinical management issues may contribute to the convergence of the MDR-TB and HIV infection epidemics. To forestall disastrous consequences, infection control, rapid case detection, effective treatment, and expanded program capacity are needed urgently.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17624830     DOI: 10.1086/518665

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  170 in total

1.  Integrated, home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model of care.

Authors:  J C M Brust; N S Shah; M Scott; K Chaiyachati; M Lygizos; T L van der Merwe; S Bamber; Z Radebe; M Loveday; A P Moll; B Margot; U G Lalloo; G H Friedland; N R Gandhi
Journal:  Int J Tuberc Lung Dis       Date:  2012-06-05       Impact factor: 2.373

2.  Vaccination of guinea pigs using mce operon mutants of Mycobacterium tuberculosis.

Authors:  Andrés Obregón-Henao; Crystal Shanley; María Verónica Bianco; Angel A Cataldi; Randall J Basaraba; Ian M Orme; Fabiana Bigi
Journal:  Vaccine       Date:  2011-04-22       Impact factor: 3.641

3.  Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it?

Authors:  S D Lawn; A D Harries; B G Williams; R E Chaisson; E Losina; K M De Cock; R Wood
Journal:  Int J Tuberc Lung Dis       Date:  2011-05       Impact factor: 2.373

4.  Averting epidemics of extensively drug-resistant tuberculosis.

Authors:  Sanjay Basu; Gerald H Friedland; Jan Medlock; Jason R Andrews; N Sarita Shah; Neel R Gandhi; Anthony Moll; Prashini Moodley; A Willem Sturm; Alison P Galvani
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-13       Impact factor: 11.205

5.  Extensively drug-resistant tuberculosis: lessons from the US experience.

Authors:  Janet R Maurer
Journal:  Curr Infect Dis Rep       Date:  2009-05       Impact factor: 3.725

Review 6.  The transmission and control of XDR TB in South Africa: an operations research and mathematical modelling approach.

Authors:  S Basu; A P Galvani
Journal:  Epidemiol Infect       Date:  2008-07-07       Impact factor: 2.451

Review 7.  Updated diagnosis and treatment of childhood tuberculosis.

Authors:  Shou-Chien Chen; Kwo-Liang Chen; Kou-Huang Chen; Shun-Tien Chien; Kow-Tong Chen
Journal:  World J Pediatr       Date:  2013-02-07       Impact factor: 2.764

Review 8.  Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis.

Authors:  Kwonjune J Seung; Salmaan Keshavjee; Michael L Rich
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-27       Impact factor: 6.915

Review 9.  Epidemiology and treatment of multidrug resistant tuberculosis.

Authors:  Carole D Mitnick; Sasha C Appleton; Sonya S Shin
Journal:  Semin Respir Crit Care Med       Date:  2008-09-22       Impact factor: 3.119

Review 10.  The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis.

Authors:  Borna Müller; Sonia Borrell; Graham Rose; Sebastien Gagneux
Journal:  Trends Genet       Date:  2012-12-13       Impact factor: 11.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.